Lipid-lowering therapy in patients with peripheral arterial disease.
Peripheral arterial disease (PAD) is a prevalent, chronic, and progressive atherosclerotic disease process involving the conduit vessels of the extremities. Most patients who present with objective signs of PAD are asymptomatic. These patients are at an increased risk of dying from cardiovascular events. Lipid management is the mainstay of risk-factor modification for patients with cardiovascular disease. Some evidence suggests that hypocholesterolemic drugs may halt the progression of atherosclerotic peripheral vascular disease. More recently, treatment with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors have demonstrated improved function in patients with symptomatic peripheral vascular disease. This paper reviews the role of lipid therapy in patients with peripheral arterial disease with focus on functional improvement and symptomatic relief based on the available data.
Ebrahimi
Ramin
R
Division of Cardiology, Greater Los Angeles VA Medical Center, Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA. ramin.ebrahimi@med.va.gov
Saleh
Jahandar R
JR
Toggart
Edward J
EJ
Hayatdavoudi
Baubac
B
Wolf
Christopher J
CJ
Wadhani
Nitin N
NN
Shah
Atman P
AP
D002318:Cardiovascular Diseases / Q000209:etiology* / Q000517:prevention & control*; D017023:Coronary Angiography; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000150:complications* / Q000188:drug therapy*; D016491:Peripheral Vascular Diseases / Q000150:complications* / Q000188:drug therapy*; D011788:Quality of Life; D012307:Risk Factors; D016896:Treatment Outcome
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors